Table 2.

Clinical tolerated doses of RNA-based medicines.

Name	Company	Bases	Formulation	ROA	Target	Highest dose reported with favorable safety profile	Ref
mRNA-1893	Moderna	Modified	Internal LNP	Intramuscular	Zika	30 µg (interim reporting, 100 and 250 µg doses pending)	[85]
VAL-506440; VAL-339851	Moderna	Modified	Internal LNP	Intramuscular, Intradermal	Influenza	100 µg (IM), 50 µg (ID)	[86, 87]
mRNA-1273	Moderna	Modified	Internal LNP	Intramuscular	SARS-CoV-2	100 µg	[7, 87, 88]
BNT162b2	Pfizer/BioNTech	Modified	Acuitas LNP	Intramuscular	SARS-CoV-2	30 µg	[89, 90]
CVnCoV	CureVac	Unmodified	Acuitas LNP	Intramuscular	SARS-CoV-2	12 µg	[91]
ARCT-21	Arcturus	Unmodified	Internal LNP	Intramuscular	SARS-CoV-2	7.5 µg	[14]
LNP-nCoVsaRNA	ICL/VaxEquity	Unmodified	Internal LNP	Intramuscular	SARS-CoV-2	10 µg	[15]
CORAL (BOOST)	Gritstone	Unmodified	Genevant LNP	Intramuscular	SARS-CoV-2	10 µg (interim reporting, 30 µg dose pending)	[92]
MRT5500	Translate Bio	Unmodified	Internal LNP	Intramuscular	SARS-CoV-2	45 µg (no DLTs reported)	[93, 94]
CV7202	CureVac	Unmodified	Acuitas LNP	Intramuscular	Rabies	2 µg	[95]
SLATE/GRANITE	Gritstone	Unmodified	Genevant LNP	Intramuscular	Neoantigens	300 µg	[96]
BI1361849 (CV9202)	CureVac	Unmodified	Protamine	Intramuscular	Prostate Cancer	1920 µg	[97]
MRT5005	Translate Bio	Unmodified	Internal LNP	Nebulization	Cystic Fibrosis	SAD: 24 mg MAD: 16 mg	[37]